A4i

What A4i does

A4i (App4Independence) is a Toronto-based digital health company that operates a B2B SaaS platform for the management of severe mental illness (SMI), spun out of the Centre for Addiction and Mental Health (CAMH) in 2018 as a joint venture with MEMOTEXT Corp. The platform consists of a patient-facing mobile application, a clinical portal for providers, and condition-specific modules including A4i-O for opioid use disorder (OUD), a Motivational JoyKit, peer support programming, and a patent-pending Audio Hallucination Tool. Underlying technology includes AI-driven wellness detection, predictive analytics for relapse risk, and anomaly detection that flags medication adherence escalations to clinicians, with the platform operating under HIPAA and PIPEDA compliance frameworks.

The company sells multi-year enterprise contracts to health systems, Certified Community Behavioural Health Clinics (CCBHCs), and public-sector behavioural-health organisations, with a current footprint that spans Riverside County in California and Ontario, Canada. Commercial validation is anchored by a November 2025 multi-year contract with Riverside County covering a 102-participant pilot, a June 2025 partnership with Waypoint Centre for Mental Health Care, and an MHCC Assessed Badge awarded in March 2026 that supports procurement in Canadian health authorities. Revenue is supplemented by non-dilutive grant funding, including approximately CAD $100,000 received through TIAP and OBIO programmes in March 2025. Customer concentration is high given the limited named-account base, and the platform competes within an emerging digital mental health market segment where regulatory credentials, clinical provenance from CAMH, and integration depth into behavioural-health workflows are the primary differentiators.

Name

A4i

Legal name

A4i Inc.

Website

https://a4i.me

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

A4i (App4Independence) is a Toronto-based B2B SaaS digital health platform that supports health systems and CCBHCs in managing patients with severe mental illness and opioid use disorder through a mobile app, clinical portal, and AI-driven wellness detection.

Ownership category

akta.pro rank

Product category

Digital Mental Health Software

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Health Services (8000)

akta.pro primary industry

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

akta.pro secondary industry

Behavioral Health & Substance Use Remote Monitoring (HLACAFAD)

Keywords

• Digital mental health platform
• Severe mental illness software
• Behavioral health SaaS
• Clinical patient portal
• Opioid use disorder treatment

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare System SaaS Subscription: B2B SaaS licensing to health systems, CCBHCs, and behavioral health organizations. Multi-year contracts with health system procurement (e.g., Riverside County multi-year contract). Revenue derived from platform access fees for clinical portal and mobile app deployment.
2. Medicaid/Insurance Billing Support: Clinical portal supports clinician and certified peer support specialist Medicaid billing codes. Captures care activity and care coordination to maximize billable events, generating indirect revenue through healthcare system cost savings and billing optimization.
3. Non-Dilutive Funding (Research/Development): Government and institutional funding for AI analytics development ($100,000 CAD from TIAP/OBIO), commercialization support (Ontario Brain Institute), and pilot programs (Help@Hand California).

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

A4i (App4Independence) sells a digital health platform consisting of a mobile application for individuals with severe mental illness (schizophrenia, psychosis, opioid use disorder) and a clinical web portal for care teams. The platform delivers AI-driven wellness detection, medication adherence reminders, mood and sleep tracking, secure peer-to-peer support, and a patent-pending auditory hallucination detector. It is licensed B2B to health systems, CCBHCs, public health agencies, and pharmaceutical partners.

Product overview

A4i (App4Independence) is a digital health platform consisting of two integrated components: a mobile application for individuals with severe mental illness (SMI) and a web-based clinical portal for care teams. The platform includes two main product streams—A4i for schizophrenia and psychosis, and A4i-O for opioid use disorder—offering features including AI-driven wellness detection, medication reminders, peer engagement, auditory hallucination coaching, and risk prediction. The platform enables care coordination between patients, peer support specialists, and clinical staff.

Differentiator

Problem solved

Functional benefit

Brands

• A4i-O: Digital platform branch specifically designed for individuals with Opioid Use Disorder (OUD), featuring co-designed content and tools developed through focus groups with lived experience individuals and care teams
• JoyKit

Products and services

• App4Independence (A4i) Mobile Application Mobile application designed to improve outcomes for individuals with severe mental illness including schizophrenia and psychosis. Provides medication reminders, mood and sleep tracking, secure peer engagement, content segmentation, and audio hallucination coaching for end users.
• A4i-O (Opioid Use Disorder Platform) Specialized version of the A4i platform for individuals with opioid use disorder, including co-designed focus-group-validated content and the Motivational JoyKit tool for treatment motivation.
• A4i Clinical Portal Web-based portal for healthcare providers, clinical staff, and certified peer support specialists to monitor patient status, view submitted notes and check-ins, manage care plans, coordinate billing, and receive AI-driven risk detection alerts.
• Peer Support Programming Service B2B peer support service offering that partners with behavioral health care teams and CCBHCs to facilitate peer engagement, providing tools for personalized care and access to patient data enabling Medicaid billing code capture for certified peer support specialists.

Quantifiable outcome

• 2.5:1 return on investment for health system customers
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature9 records

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

• Mental Health Commission of Canada (MHCC)coreStrategic or Co-development Partner · 30 March 2026A4i received MHCC Assessed Badge following rigorous assessment against national standards. Collaboration between CAMH, MEMOTEXT, ORCHA, and MHCC.
• ORCHA (Organisation for the Review of Care and Health Apps)coreTechnology or Integration · 30 March 2026Collaborated with MHCC and A4i for app assessment against Mental Health Commission of Canada's Assessment Framework standards.
• Riverside University Health System - Behavioral Health (RUHS-BH)flagshipStrategic or Co-development Partner · 3 November 2025After successful 2-year pilot, RUHS-BH procured A4i for county-wide adoption across all clinics in Riverside County, California. Pilot launched 2021 as part of Help@Hand California Statewide Collaborative. A4i delivered 2.5:1 ROI and double-digit hospital readmission reduction.
• Waypoint Centre for Mental Health CarecoreStrategic or Co-development Partner · 12 June 2025Partnership to implement A4i's 'health at home' initiative for patients transitioning from inpatient care or using community services. Funded by OBIO's Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence. Waypoint covers large rural geographical area in Ontario.
• Plug and Play CanadaminorGTM or Marketing Partner · 23 October 2024Selected for Startup Immersion Program run by Plug and Play Canada in collaboration with OCIF. CEO Amos Adler pitched at Silicon Valley Summit.
• The Royal Ottawa Mental Health CentrecoreStrategic or Co-development Partner · 13 June 2024One-year evaluation project exploring feasibility of integrating A4i app and clinical portal into clinical practice at Ozerdinc Grimes Family Regional Psychosis Clinic. Funded by OBIO's Early Adopter Health Network (EAHN).
• OBIO (Ontario Bioscience Innovation Organization)coreStrategic or Co-development Partner · 12 June 2024OBIO facilitates technology evaluation through Early Adopter Health Network (EAHN) and implementation funding through LSCTC Centre of Excellence. Multiple partnerships (Royal, Waypoint) facilitated through OBIO programs.
• Centre for Addiction and Mental Health (CAMH)flagshipStrategic or Co-development Partner · 10 April 2024A4i founded in 2018 as spin-off from CAMH, co-created with MEMOTEXT Corp. CAMH is Canada's leading mental health and addiction research hospital. Ongoing beta testing partnership for A4i-O opioid use disorder platform.
• Help@Hand California Statewide CollaborativecoreGTM or Marketing Partner · 1 January 2021Help@Hand funded initial pilot program bringing A4i to targeted patient cohort at RUHS-BH, integrating platform into daily workflows of behavioral health teams.
• MEMOTEXT Corp.flagshipStrategic or Co-development Partner · 1 January 2018MEMOTEXT is A4i's technology development partner and parent company owner. MEMOTEXT is a digital therapeutics platform for patient engagement co-creation. CEO Amos Adler serves as CEO of MEMOTEXT.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Click Therapeutics: Click Therapeutics develops prescription digital therapeutics for underserved conditions including depression and migraine, partnering with pharma. Comparable to A4i's therapy-companion approach and pharma channel.
• Pelago (formerly Quit Genius): Pelago is a digital substance use disorder platform combining coaching and medication-assisted treatment for enterprises and health plans. Comparable A4i-O substance use focus and B2B payer/employer channel.
• SilverCloud Health (Amwell): SilverCloud Health provides digital CBT and mental health programs deployed through health systems and insurers globally. Comparable B2B digital behavioral health platform sold to health systems and CCBHC-equivalent providers.
• Meru Health: Meru Health delivers a digital mental health program combining therapist-led treatment, app-based exercises, and biometric monitoring for depression, anxiety, and burnout — directly comparable as a digital therapeutic for behavioral health.
• Pear Therapeutics: Pear Therapeutics was a leading prescription digital therapeutics company targeting substance use disorder and schizophrenia with FDA-authorized products (reSET, reSET-O). A4i operates in the same prescription-adjacent DTx category for SMI and OUD.
• Big Health: Big Health produces digital therapeutics (Sleepio, Daylight) for insomnia and anxiety, sold to health systems, payers, and employers. Comparable digital-therapeutic platform with clinical evidence and B2B health system sales motion.
• Akili Interactive: Akili Interactive commercializes FDA-cleared digital therapeutics (EndeavorRx, EndeavorOTC) for cognitive and mental health conditions. Closely comparable as a regulated digital therapeutic targeting a defined patient population.

Broad incumbents

• Headspace Health: Headspace Health combines the Headspace app with Ginger's on-demand coaching/therapy to serve employer, payer, and health system mental health needs. Comparable mental health platform but at vastly larger scale and broader target audience than A4i's SMI focus.
• Lyra Health: Lyra Health is a leading mental health benefits platform serving employers with therapy, coaching, and medication management. Comparable B2B mental health distribution model but broader employer-focused rather than SMI-specific.

Emerging players

• Mahana Therapeutics: Mahana Therapeutics develops prescription digital therapeutics for GI and behavioral health conditions including IBS and tinnitus. Comparable emerging DTx player targeting a specific condition with regulatory-grade evidence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/A4i_me
• LinkedInlinkedin.com/company/a4i-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about A4i